Evolving Guidelines and Targets: When and How to Use the PCSK9 Inhibitors
Cardiology
Curriculum:
Achieving LDL Goals in Patients with Hypercholesterolemia
Achieving LDL Goals in Patients with Hypercholesterolemia
Credits:
1.5 AMA PRA Category 1 Credit(s) ™
1.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
September 13, 2016
September 13, 2016
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Primary Care Physicians; Nurse Practitioners; Physician Assistants
Relevant Terms:
Lipid management; cardiovascular disease; athersclerosis; familial hypercholesterolemia; dyslipidemia
Christopher Paul Cannon, MD
Christopher Paul Cannon, MD
Executive Director, Cardiometabolic Trials,
Harvard Clinical Research Institute
Cardiovascular Division, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School
Boston, MA
Bio
Dr. Cannon is a senior investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, leading trials such as TACTICS-TIMI 18, PROVE IT-TIMI 22, and CLARITY-TIMI 28. He earned his MD from Columbia University College of Physicians and Surgeons in New York, and after completing his residency in internal medicine at Columbia Presbyterian Medical Center, he was a cardiovascular fellow at Brigham and Women's Hospital.
Dr. Cannon has published over 500 original articles, reviews, book chapters or electronic publications on the topic of acute coronary syndromes, including works in Circulation, Journal of the American College of Cardiology, Lancet, and the New England Journal of Medicine. He has received numerous awards, including the Alfred Steiner Research Award, and the Upjohn Achievement in Research Award, and he serves as Chairman for several ACC and AHA committees.
He is editor-in-chief of the ACC's Website, Cardiosource (www.cardiosource.com) as well as the journal Critical Pathways in Cardiology and a 40-book series Contemporary Cardiology. He has authored or edited 10 books, including the New Heart Disease Handbook for patients.
| 1. | Discuss the limitations of currently available lipid-lowering agents and the need for novel treatment options | 2. | Describe the mechanism of action, efficacy and safety of PCSK9 inhibitors and what differentiates them from other forms of lipid-lowering therapy |
| 3. | Review the clinical trial data supporting the use of PCSK9 inhibitors to lower LDL cholesterol and ongoing outcomes trials in at-risk patients with hypercholesterolemia | 4. | Apply current evidence-based therapies to optimize control of LDL-C in patients with hypercholesterolemia |
| 1. | Discuss the limitations of currently available lipid-lowering agents and the need for novel treatment options |
| 2. | Describe the mechanism of action, efficacy and safety of PCSK9 inhibitors and what differentiates them from other forms of lipid-lowering therapy |
| 3. | Review the clinical trial data supporting the use of PCSK9 inhibitors to lower LDL cholesterol and ongoing outcomes trials in at-risk patients with hypercholesterolemia |
| 4. | Apply current evidence-based therapies to optimize control of LDL-C in patients with hypercholesterolemia |
LAUNCH DATE/EXPIRATION DATE
This activity was launched on September 13, 2016 and will expire on September 13, 2017.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of primary care clinicans, NPs, PAs and other health care professionals involved in the care of patients with dyslipidemia.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been designed to meet the educational needs of primary care clinicans, NPs, PAs and other health care professionals involved in the care of patients with dyslipidemia.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO CLAIM CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.5 AMA PRA Category 1 credits™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 75% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
| Name of Faculty | Reported Financial Relationship |
|---|---|
| Christopher Paul Cannon, MD | Dr. Cannon has received grants from Accumetrics, Arisaph, Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Janssen, Merck, and Takeda. He has consulted for Boehringer-Ingelheim, BMS, CSL Behring, Essentialis, GlaxoSmithKline, Kowa, Merck, Takeda, Lipimedix, Pfizer, Regeneron and Sanofi. |
OTHER CONTRIBUTOR DISCLOSURES
Bruce S. Stambler, M.D, Director of Cardiac Arrhythmia Research and Education at Piedmont Heart Institute in Atlanta, GA provided external review for this activity. He has received consulting fees from Medtronic.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content disclosed no relevant financial relationships with any commercial interests.
SUPPORT ACKNOWLEDGEMENT
This activity is supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above |
